Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Compumedics Limited ( (AU:CMP) ) has shared an update.
Compumedics reported record first-half FY26 performance, with sales orders rising 6% to $34.9 million and shipped and invoiced revenue jumping 32% to $30.8 million, reflecting stronger demand for its core sleep and neuro diagnostic platforms and improved delivery execution, including ongoing contributions from its MEG brain imaging systems. The company is implementing a $2 million annual cost-out program and expects H1 FY26 EBITDA to exceed $3 million, while reaffirming full-year guidance of $70 million in revenue and up to $9 million in EBITDA, supported by anticipated additional MEG orders, a stronger H2 shipment profile, the planned H2 launch of its Somfit D device to accelerate penetration in the U.S. home sleep testing market, a targeted U.S. commercial restructure, and efforts to expand bank funding capacity to back its growth and working capital needs.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.33 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited (ASX: CMP) is a global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain and ultrasonic blood flow monitoring, with a growing focus on connected, higher-margin platforms and the large U.S. home sleep testing market.
Average Trading Volume: 89,663
Technical Sentiment Signal: Buy
Current Market Cap: A$65.92M
See more insights into CMP stock on TipRanks’ Stock Analysis page.